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ess: drkanbay@yahoo.cSummary Helicobacter pylori (HP) infection may cause extradigestive manifesta-
tions directly or indirectly, by potential mechanisms. HP infection triggers a marked
local inflammatory response and a chronic systemic immune response. Some of the
mediators that are thought to be possibly involved in the pathogenesis of
extradigestive diseases caused by HP infection include IL-1, TNF-a, interferon
(IFN)-g, leukotriene C4 and platelet-activating factor. Previous epidemiological and
serological case control studies have revealed that HP infection might have a role in
the development of chronic bronchitis, bronchiectasis, lung cancer and tuberculosis.
However HP infection does not appear to have a role in the development of bronchial
asthma. Considering the importance and prevalence of respiratory system diseases,
it may be time to conduct well-designed sets of studies to clarify whether there is an
association with HP infection and respiratory system diseases, and to answer
questions that have been posed regarding the patterns of histology, genotypes of HP,
and the effects of eradication therapy. The aim of this review was to analyze the
possible association between HP and respiratory disease and provide a critical review
of the relevant literature.
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Helicobacter pylori (HP) has been conclusively
linked to different forms of gastritis, as well as to
peptic ulcer disease of the stomach and duodenum,
gastric adenocarcinoma, and low-grade gastric
lymphoma arising from mucosa-associated lym-
phoid tissue. HP may also play a role in dyspepsia
and nonulcer dyspepsia, though these connections
have not yet been proven.1–5 HP infection is
confined to the gastric mucosa and is noninvasive,
but it triggers a marked local inflammatory re-
sponse and a systemic immune response. It is
possible that HP infection of the stomach might
produce effects elsewhere by altering levels of
systemic inflammatory mediators.6–8
HP infection is very common worldwide, and has
been documented in combination with other
diseases. It is possible that concomitance with
other disorders is purely incidental, and if this is
true then assumptions about certain conditions
being caused by HP infection would be wrong, as
association does not necessarily imply causation.
It has long been known that certain infectious
agents that affect specific areas of the body can
also have systemic sequelae. A typical example of
this is infection with beta-hemolytic Streptococcus
group A. These bacteria frequently cause acute or
chronic tonsillitis, which can also lead to rheumatic
fever, cardiac inflammation, glomerulonephritis,
and neurological involvement. It has been shown
that the extrapharyngeal manifestations of the
infection are caused by cross mimicry between
bacterial and host antigens.
HP is a Gram-negative, spiral-shaped bacterium.
There are two major groups of HP isolates: type I
HP organisms express the vacuolating cytotoxin
(VacA) and the cytotoxin-associated gene (CagA),
whereas type II HP organisms express neither of
these proteins. Such strains have different patho-
genic potential. Type I strains can induce mucosal
damage by stimulating gastric epithelial cytokine
responses, and can produce a variety of other
factors that determine, directly and indirectly, the
local inflammatory response. However, the type IIHP organism does not cause mucosal damage as
much as type I HP organisms due to the absence of
VacA and CagA in type II HP organisms.9,10
Recently, it has been suggested that HP infection
may be involved in several extraintestinal disorders
(Table 1).9,11,12 This idea is based on the following:
(i) local inflammation can have systemic effects;
(ii) gastric HP infection is a chronic process that
lasts for decades; (iii) persistent infection induces
chronic inflammatory and immune responses that
can cause lesions that are local or distant from the
site of primary infection.9,13
As noted, HP infection triggers a marked local
inflammatory response and a chronic systemic
immune response. As a Gram-negative bacterium,
HP contains lipopolysaccharide a substance which
stimulates the production of many cytokines,
including interleukin (IL)-1, IL-6 and tumor necrosis
factor (TNF)-a.14,15 One hypothesis is that the
persistent inflammatory response related to HP
infection could induce vascular disorders via
immune-mediated release of substances associated
with vasospasm or platelet aggregation. Some of
the mediators that are thought to possibly be
involved in the pathogenesis of extradigestive
diseases caused by HP infection include IL-1, TNF-
a, interferon (IFN)-g, leukotriene C4 and platelet-
activating factor (Fig. 1).16,17
Many respiratory disorders, such as chronic
bronchitis, bronchiectasis, asthma, lung cancer
and tuberculosis, feature chronic inflammation
and increased immune response. In addition, it is
well known that patients with peptic ulcers have
higher rates of chronic bronchitis and lung cancer
than individuals who are ulcer-free.18–23 Sandulea-
nu et al.24 showed that HP infected patients on
long-term acid inhibition displayed three features:
(i) non-HP bacterial growth, increased cytokine
levels, and a high prevalence of corpus atrophic
gastritis; (ii) the development of atrophic gastritis
during acid-suppressive therapy was associated
with a simultaneous gastric infection with HP and
non-HP bacteria; (iii) the type of interaction
between HP and non-HP bacteria was synergistic.
Taken together, these findings indicate that double
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Table 1 Extradigestive disorders associated with
H. pylori infection.
Respiratory disorders
Chronic obstructive pulmonary disease
Bronchiectasis
Lung cancer
Pulmonary tuberculosis
Bronchial asthma
Vascular disorders
Ischemic heart disease
Stroke
Primary Raynaud phenomenon
Primary headache
Autoimmune disorders
Sjo¨gren’s syndrome
Scho¨nlein–Henoch purpura
Autoimmune thrombocytopenia
Autoimmune thyroiditis
Parkinson’s disease
Skin disorders
Idiopathic chronic urticaria
Rosacea
Alopecia areata
Other disorders
Sideroblastic anemia
Growth retardation
Liver cirrhosis
Diabetes mellitus
Sudden infant death
Host specific
immunological response 
Mast cells
 
secretion
Autoantibodies 
- IL-1     - IL-12 
- PG       - LT -Fibrinogen
-Heat shock proteins 
-Others
Cytotoxin
(CagA, VacA)  
- INF α, β, Y
- TNF-α - PAF
Figure 1 Schematic presentation of secretion of sub-
stances of H. pylori after colonization of H. pylori in the
gastric mucosa11 (LT, Leukotriene; PG, prostaglandin;
PAF, platelet activating factor; IL, interleukin; INF,
interferon; TNF, tumor necrosis factor).
Helicobacter pylori infection as a possible risk factor for respiratory system disease 205gastric infection with HP and non-HP bacteria may
play a major role in the development of atrophic
gastritis. Rising gastric pH levels induced by HP,
non-HP infection and acid suppressive therapy may
promote bacterial growth and thereby increase the
risk of pneumonia. Recently, Laheij et al.25 showed
that subjects using acid suppressive drugs moreoften reported clinical manifestations of respira-
tory tract infections and complications compared
with those who does not use acid-suppressive
drugs. The aim of this review was to analyze the
association between HP and respiratory disease and
provide a critical review of the relevant literature.Lung cancer and HP
The World Health Organization’s International
Agency for Research on Cancer recommends that
HP be classified as a group I carcinogen.26 The
prevalence of lung cancer in patients with peptic
ulcers is two to three times higher than that in
people who are ulcer-free.27 One possible explana-
tion for this is the high prevalence of smoking in
both groups. In a pilot study of 50 Polish patients
with lung cancer, Gocky et al.28 found a very high
seroprevalence of HP (89.5%) and speculated that
this might be involved in lung carcinogenesis. The
authors emphasized that HP should be eradicated
from lung cancer patients to eliminate HP-induced
hypergastrinemia and reduce COX-2 expression.28
In addition, there were more CagA- and VacA-
positive lung cancer cases than controls; however,
only VacA seropositivity showed a statistically
significant association with occurrence of lung
cancer.28 Ece and coworkers found a significantly
higher frequency of HP seropositivity in lung cancer
patients than in control subjects.29–31 Philippou
et al.32 carried out a case-control study involving a
sample of 78 Greek patients with lung cancer and
68 control subjects. Their data revealed no
significant association between HP infection and
lung cancer.
HP infection may contribute to lung cancer by
upregulating gastrin and COX-2, which could
stimulate tumor growth and angiogenesis.33 The
lungs develop from the same endodermal cells that
form the lining of the gastrointestinal tract, and
both these systems contain cells that release
various hormonal peptides.34 Increased plasma
concentration of gastrin due to HP infection may
contribute to lung carcinogenesis by inducing
proliferation of mucosal cells in the bronchial
epithelium.35 Moreover, if HP is inhaled or its
exotoxins are aspirated, these substances could
accumulate in lung tissue. However, to date, HP has
not been identified in human bronchial tissue or
isolated from bronchoalveolar lavage fluid.36
In summary, HP infection may be associated with
the development of lung cancer. However, further
studies with larger numbers of patients are needed
to further elucidate the potential pathogenetic
relationship between HP infections and lung cancer.
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According to three epidemiological studies carried
out between 1968 and 1986, the prevalence
rates of chronic bronchitis in patients with peptic
ulcers are two to three times higher than the
corresponding rates in ulcer-free controls.37–39
Moreover, a follow-up study revealed that chronic
bronchitis is a major cause of death among patients
with peptic ulcer disease.40 Literature on the link
between HP infection and chronic bronchitis has
not been identified to date, but it is clear that
cigarette smoking is the major factor underlying
the association between HP and chronic bronchi-
tis.41–43 Interestingly, however, a 1998 pilot study
conducted on a small number of Italian patients
showed that HP infection might increase the risk of
developing chronic bronchitis.41 A more recent
epidemiological study in Danish adults suggested
that chronic bronchitis might be more prevalent in
women who are positive for HP immunoglobulin (Ig)
G than in women who tested negative for this
antibody.42 Gaselli et al.41 in the above-mentioned
study from Italy, found an 81.6% seroprevalence of
HP in 60 consecutive patients with chronic bron-
chitis and 57.9% seroprevalence of HP in 69 control
subjects (P ¼ 0:008). In addition, Roussos et al.43
found significantly higher rates of seropositivity for
anti-HP and anti-CagA antibodies in chronic bron-
chitis patients than in control subjects.
Research has not yet identified mechanisms for
this putative link between HP infection and chronic
bronchitis. One possibility is that chronic induction of
inflammatory mediators by HP infection leads to the
development of chronic bronchitis. The increased
prevalence of CagA-positive HP strains in chronic
bronchitis patients supports this hypothesis.43 It is
well known that these virulent strains stimulate the
release of a variety of proinflammatory cytokines,
including IL-1, IL-8 and TNF-a,44,45 and that serum
cytokine levels normalize after HP is eradicated.46
These cytokines are also thought to be involved in
the pathogenesis of chronic bronchitis.47–49 There-
fore, HP infection in general, and infection with
CagA-positive strains in particular, might play a
proinflammatory role in chronic bronchitis and act
as a co-trigger with other more specific environ-
mental, genetic and unknown factors.
Another potential pathogenetic mechanism could
be inhalation of HP or aspiration of its exotoxins
into the respiratory tract, which might also cause
chronic airway inflammation like that, which occurs
in chronic bronchitis. However, as mentioned
above, no HP species have yet been detected in
human bronchial tissue or isolated from bronchoal-
veolar lavage fluid.50In summary, the primary evidence for an associa-
tion between HP infection and chronic bronchitis
has come from serology-based case-control studies.
Research on the relative risk of developing chronic
bronchitis in the setting of HP infection is required.
As well, there is a need to investigate how HP
eradication affects the natural history of chronic
bronchitis, and the pathogenetic mechanisms
that underlie the association between HP infection
and this disease. Future studies should concentrate
on the prevalence of CagA-positive HP strains
and the proinflammatory markers they induce in
patients with chronic bronchitis. Considering
the importance of chronic bronchitis, it may be
time to conduct well-designed sets of studies to
clarify whether there is an association with HP
infection, and to answer questions that have
been posed regarding the patterns of histology,
genotypes of HP, and the effects of eradication
therapy.Bronchiectasis and HP
Tsang et al.51 detected a high seroprevalence of HP
(76%) in patients with bronchiectasis, and found
that this rate was significantly higher than rates
they observed in healthy volunteers (54.3%) and
tuberculosis patients (52.9%). The authors found
that the patients with bronchiectasis who were
sputum producers had a significantly higher HP
seroprevalence (83.1%) than the nonproducers
(58.6%) (P ¼ 0:0002). To our knowledge, this study
is the only one in the literature that has focused on
HP infection in relation to bronchiectasis.
With regard to the pathogenesis of bronchiectasis
in the setting of HP infection, HP-induced chronic
activation of inflammatory mediators might lead to
the development of this bronchial condition. HP
infection causes an extensive recruitment of poly-
morphs and T lymphocytes into the gastric submuco-
sa,40,41 and also causes release of cytokines,
particularly IL-8, TNF-a and IL-1.51 As noted above,
it is also possible that inhalation of HP or aspiration of
HP exotoxins might lead to chronic airway inflamma-
tion, as occurs in bronchiectasis. However, as far as
we know, neither identification of HP species in
human bronchial tissue, nor isolation of HP from
bronchoalveolar lavage has yet been achieved.52
In conclusion, HP is common in patients with
chronic bronchiectasis. However, the mechanism
underlying the suggested association between HP
infection and bronchiectasis remain unclear. Future
studies should be planned to identify the effect of
CagA positive HP infection on the natural history of
bronchiectasis and on proinflammatory markers.
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In a different study from the one mentioned above,
Tsang et al.53 investigated a cohort of 90 Chinese
patients with bronchial asthma and found that
the HP seroprevalence in this group was not
significantly different from the rate in control
subjects. They also found that, in the asthma
patients, serum HP IgG level was not correlated
with predicted FEV1, predicted FVC% or duration of
asthma (P40:05). The authors concluded that HP
infection is not involved in the pathogenesis of
asthma. In addition, Jun et al.54 found that there
was no significant difference in both anti-HP IgG
and anti-HP-CagA IgG levels between the asthmatic
and control subjects (P40:05), but the mean level
for the peptic ulcer group was significantly higher
than that of asthmatic group (Po0:01). They did
not find a relationship between asthma and HP
infection. There are insufficient data to be certain
whether or not there is a relationship between
HP infection and asthma and further studies are
warranted.Tuberculosis and HP
It is well known that patients with peptic ulcers are
more prone to tuberculosis than individuals who are
ulcer-free.27 Previous studies have indicated that
patients with tuberculosis may have a higher pre-
valence of HP infection than the healthy population.55
Filippou et al.56 conducted a study in Greece and
observed 87.5% seroprevalence of HP in 80 consecutive
patients compared to a significantly lower 61.4% in 70
controls (P ¼ 0:004). Mitchell et al.57 studied in China,
and their data indicated that history of pulmonary
tuberculosis might be associated with increased
prevalence of HP infection. However, Sanaka et al.58
performed a serology-based case-control study in a
hospitalized population and found no significant
difference in HP seroprevalence between a group of
40 inpatients who had been on anti-tuberculosis
therapy for more than 3 months and a group of 60
control inpatients. In addition, Tsang et al.51 showed
no differences in seroprevalence of HP between
healthy volunteers and patients with tuberculosis.
In addition, the HLA-DQ serotype may contribute
to enhanced mycobacterial survival and replica-
tion.58 The same serotype is also associated with
increased susceptibility to HP infection.59,60
Currently, our knowledge about the possible
connection between HP infection and tuberculosis
is entirely based on serologic case-control studies,
and the pathogenetic mechanisms involved remain
unclear.Conclusion
In summary, the primary evidence for an association
between HP infection and respiratory system disease
has come from serology-based case-control studies.
Research on the relative risk of developing respira-
tory system disease in the setting of HP infection is
required. There is also a need to investigate how HP
eradication effects respiratory system disease and
the pathogenetic mechanisms that underlie the
association between HP infection and respiratory
system disease. Future studies should concentrate
on the prevalence of CagA-positive HP strains and
the proinflammatory markers they induce in patients
with respiratory system disease. It may be time to
conduct well-designed sets of studies to clarify
whether there is an association with HP infection,
and to answer questions that have been posed
regarding the patterns of histology, genotypes of HP,
and the effects of eradication therapy.References
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